Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-12-04
2007-12-04
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S205100
Reexamination Certificate
active
11238155
ABSTRACT:
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
REFERENCES:
patent: 2004/0146528 (2004-07-01), Moss et al.
patent: WO 02/072754 (2002-09-01), None
patent: WO 2006/026667 (2006-03-01), None
Kusumi et al. Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity In Vivo and after Cocultivation in Vitro. Journal of Virology, Feb. 1992, vol. 66, No. 2, p. 875-885.
Meyerhans et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequenctial HIV isolations. Cell, Sep. 8 1989, vol. 58, p. 901-910.
Altman et al. HIV escape: there and back again. Nature Medicine, Mar. 2004, vol. 10, No. 3, p. 229-230.
Friedrich et al. Reversion of CTL escape—variant immunodeficiency viruses in vivo. Nature Medicine, Mar. 2004, vol. 10, No. 3, p. 275-281.
Leslie et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Medicine, Mar. 2004, vol. 10, No. 3, p. 282-289.
Desrosiers. Prospects for an AIDS vaccine. Nature Medicine, Mar. 2004, vol. 10, No. 3, p. 221-223.
Voe Laer et al. Gene therapy for HIV infection: what does it need to make it work? The Journal of Gene Medicine 2006, vol. 8, p. 658-667.
Whitney et al. Live attenuated HIV vaccines: pitfalls and prospects. Current Opinion in Infectious Diseases 2004, vol. 17, p. 17-26.
Yee et al. Prospects for Gene Therapy Using HIV-Based Vectors. Somatic Cell and Molecular Genetics, Nov. 2001, vol. 26, Nos. 1/6, p. 159-174.
Pakula et al. Genetic analysis of protein stability and function, Annual Review of Genetics 1989, vol. 23, p. 289-310. Abstract only provided.
Oestreicher et al. A Single Amino Acid Change in a Pathway-specific Transcription Factor Results in Differing Degrees of Constitutivity, Hyperinducibility and Derepression of Several Structural Genes, Journal of Molecular Biology 1995, vol. 249, p. 693-699.
Allen, T.M. et al., 2000 “Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus ankara boost regimen”J. Immunol.164:4968-4978.
Amara, R.R. et al., 2001 “Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA Vaccine”Science292: 69-74.
Barouch, D.H. et al., 2000 “Control of viremia and prevention of clinical AIDS in rhesus monkeys to cytokine-augmented DNA vaccination”Science290:486-492.
Egan, M.A. et al., 2000 “Simian immunodeficiency virus (SIV)gagDNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection”J. Virol.74:7485-7495.
Gorelick, R.J. et al., 1999 “Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivo”Virology253:259-270.
Goulder, P.J. et al., 1999 “Anti-HIV cellular immunity: recent advances towards vaccine design”AIDS(Suppl. A) 13:S121-S136.
Harris, M.E. et al. 2002 “Among 46 near full-length HIV type 1 genome sequences from rakai district, uganda, subtype D and AD recombinants predominate”AIDS Res. Hum. Retrovir.18:1281-1290.
Hirsch, V.M. et al. 1995 “Limited virus replication following SIV challenge of macaques immunized with attenuated MVA vaccinia expressing SIVsmenvandgag-pol” Vaccines95:195-200.
Hofmann-Lehmann, R. et al., 2000 “Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one-versus two-enzyme systems”AIDS Res. Hum. Retrovir.16:1247-1257.
Karacostas, V. et al., 1989 “Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector”PNAS USA86:8964-8967.
Karlsson, G.B. et al., 1997 “Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+lymphocyte depletion in rhesus monkeys”J. Virol.71:4218-4225.
Lechner, F. et al., 2000 “Analysis of successful immune responses in persons infected with hepatitis C virus”J. Exp. Med.191:1499-1512.
Mellors, J.W. et al., 1996 “Prognosis in HIV-1 infection predicted by the quantity of virus in plasma”Science272:1167-1170.
Montefiori, D.C. et al., 1998 “Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1”J. Virol.72:3427-3431.
Montefiori, D.C. et al., 1988 “Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay”J. Clin. Microbiol.26:231-235.
Ourmanov, I. et al., 2000 “Comparative efficacy of recombinant modified vaccinia virus ankara expressing simian immunodeficiency virus (SIV) gag-pol and/or env in macaques challenged with pathogenic SIV”J. Virol.74:2740-2751.
Power, C.A et al., 1999 “A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells”J. Immunol. Methods227:99-107.
Quinn, T.C. et al., 2000 “Viral load and heterosexual transmission of human immunodeficiency virus type 1”N. Engl. J. Med.342:921-929.
Robinson, H.L. et al., 2000 “AIDS vaccines: heterologous prime/boost strategies for raising protective T cell responses”AIDS Rev.2:105-110.
Robinson, H.L. et al., 1999 “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations”Nature Med.5:526-534.
Sauter, M.M. et al., 1996 “An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface”J. Cell Biol.132:795-811.
Waldrop, S.L. et al., 1997 “Determination of antigen-specific memory/effector CD4+T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency”J. Clin. Invest.99:1739-1750.
Earl Patricia L.
Eller Leigh Anne
Harris Matthew Edward
Moss Bernard
VanCott Thomas C.
Campell Bruce R.
Henry M. Jackson Foundation for the Advancement of Military Medi
Humphrey Louise
Knobbe Martens Olson & Bear LLP
The Government of the United States of America, as represented b
LandOfFree
MVA expressing modified HIV envelope, gag, and pol genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MVA expressing modified HIV envelope, gag, and pol genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MVA expressing modified HIV envelope, gag, and pol genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876456